CCNE1 Amplification and Cyclin E: Biology and Testing Context

What Cyclin E Does

Cyclin E1 accumulates in late G1 and binds CDK2. Cyclin E-CDK2 completes the phosphorylation of RB that CDK4/6 begins, and it also licenses replication origins and promotes centrosome duplication.

Cyclin E is normally expressed in a tight pulse and then degraded via the SCF-FBXW7 ubiquitin ligase. Loss of FBXW7 or CCNE1 amplification both raise cyclin E levels outside that pulse.

Where CCNE1 Amplification Occurs

CCNE1 amplification is found in roughly one in five high-grade serous ovarian cancers and also in subsets of endometrial, gastro-oesophageal, breast and bladder cancers.

It tends to be mutually exclusive with BRCA1/2 loss in ovarian cancer and is generally associated with a less favourable outcome in that setting.

Link to CDK4/6 Inhibitor Resistance

Because cyclin E-CDK2 can drive RB phosphorylation independently of CDK4/6, high cyclin E activity provides a route around CDK4/6 inhibition.

High CCNE1 or cyclin E expression has been associated with shorter benefit from CDK4/6 inhibitors in hormone-receptor-positive breast cancer in retrospective analyses, though it is not used as a standalone treatment-selection test.

Emerging Synthetic-Lethal Approaches

CCNE1-amplified cells carry high replication stress and depend on checkpoint kinases to survive mitosis. Screens identified PKMYT1 as synthetic lethal with CCNE1 amplification, leading to the clinical PKMYT1 inhibitor lunresertib.

WEE1 and CDK2-selective inhibitors are being explored on the same rationale. These strategies remain investigational.

Testing Considerations

CCNE1 status can be assessed by DNA copy number (FISH or sequencing) or by cyclin E protein expression; these do not always agree, and amplification does not guarantee high protein.

Copy-number thresholds, tumour purity and assay platform all influence the call, so the method should be recorded with the result.

Key Takeaways

• ·CCNE1 encodes cyclin E1, which activates CDK2 to drive G1/S.
• ·Amplification is common in high-grade serous ovarian cancer and several other tumours.
• ·High cyclin E activity can bypass CDK4/6 inhibition.
• ·PKMYT1 and WEE1 inhibition are investigational synthetic-lethal strategies; DNA and protein tests can disagree.